Model input parameters for a Monte Carlo simulation of HCV.

<p>S.D. = standard deviation; PY = person-year; PEG = pegylated interferon; RBV = ribavirin; TPV = telaprevir; SVR = sustained virologic response; ICM = integrated case management; IFN = interferon.</p>a<p>The lifetime probability of linking to HCV care upon receipt of a positive antibody result is 66%.</p>b<p>In the interferon-free scenario, we assumed that 54% of those linked to care would initiate therapy.</p>c<p>Costs varied as a function of age and sex.</p>d<p>Includes the cost of a RNA confirmatory test and a nursing visit.</p>e<p>ntervention costs are presented on a per participant basis, assuming that the participant completes the entire intervention. During the simulation, participants accrued costs on a monthly basis. If the participant was lost to follow-up, or otherwise withdrew from care before the end of the intervention, then that patient stopped accruing intervention costs at the time of being lost (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0097317#pone.0097317.s001" target="_blank">Appendix S1</a> for details).</p>f<p>Treatment visit costs are higher in the first month compared to other months.</p>g<p>13% of patients received a reduced weekly dose of 135 mcg in response to non-treatment ending neutropenia <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0097317#pone.0097317-Food1" target="_blank">[45]</a>.</p>h<p>RBV dose was a function of genotype (genotype 1 = 1,200 mg/day; genotype 2 or 3 = 800 mg/day). In addition, 36% of patients on triple therapy and 17% on dual therapy were treated with reduced dose RBV = 600 mg/day in response to non-treatment ending anemia <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0097317#pone.0097317-Food1" target="_blank">[45]</a>.</p>i<p>Only patients with genotype 1 receive TPV for treatment months 1–3.</p>j<p>13% of patients developed non-treatment ending neutropenia (absolute neutrophil count <750/ml) and received filgrastim 300 mcg/two times weekly <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0097317#pone.0097317-Food1" target="_blank">[45]</a>.</p>k<p>Only patients with genotype 1 treated with PEG/RBV/TPV therapy received 150g/month for treating mild rash (28% during the first 3 months of therapy) <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0097317#pone.0097317-Food1" target="_blank">[45]</a>.</p>l<p>The range reflects the fact that some patients were treated for 6 months, while those without rapid virologic response were treated for 12 months.</p>m<p>Reflects lower quality of life for individuals with HCV risk-factors such as substance use.</p>n<p>This utility weight was multiplied by an individual’s health state utility during the months that a patient was receiving HCV therapy without major toxicity. For example, a patient with HCV and mild to moderate fibrosis who underwent HCV treatment had a utility = 0.801 (0.90×0.89) during the months that (s)he was on medications.</p>o<p>This utility “toll” was subtracted from a patient’s health state utility during the month of a major toxicity event.